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Abstract 
Distraction osteogenesis after post-traumat-
ic segmental bone loss of the tibia is a complex
and time-consuming procedure that is often
complicated due to prolonged consolidation or
complete insufficiency of the regenerate. The
aim of this feasibility study was to investigate
the potential of bone marrow aspiration con-
centrate (BMAC) for percutaneous regenerate
augmentation to accelerate bony consolidation
of the regenerate. Eight patients (age 22-64)
with an average posttraumatic bone defect of
82.4 mm and concomitant risk factors (nico-
tine abuse, soft-tissue defects, obesity and/or
circulatory disorders) were treated with a mod-
ified  Ilizarov  external  frame  using  an
intramedullary cable transportation system. At
the end of the distraction phase, each patient
was treated with a percutaneously injection of
autologous BMAC into the centre of the regen-
erate. The concentration factor was analysed
using flow cytometry. The mean follow up after
frame removal was 10 (4-15) months. With a
mean healing index (HI) of 36.9 d/cm, bony
consolidation of the regenerate was achieved
in all eight cases. The mean concentration fac-
tor of the bone marrow aspirate was 4.6 (SD
1.23).  No  further  operations  concerning  the
regenerate were needed and no adverse effects
were observed with the BMAC procedure. This
procedure can be used for augmentation of the
regenerate in cases of segmental bone trans-
port. Further studies with a larger number of
patients and control groups are needed to eval-
uate a possible higher success rate and accel-
erating effects on regenerate healing.
Introduction
Distraction  osteogenesis  for  segmental
bone defect reconstruction is an established
procedure. However, the long duration of the
time in external fixation is often cause of con-
siderable  morbidity  and  high  complication
rates. The therapeutic potential of facilitating
callus  maturation  lies  in  both  reducing  the
healing index in more basic cases and increas-
ing the success rates in more difficult cases.
Currently, augmentation with percutaneously
applied adjuvants to reduce consolidation time
has been designated as one of the major goals
for future research in distraction osteogene-
sis.1 There is already clinical evidence that the
application of cells can accelerate healing of
the  regenerate:  Kitoh  et  al.2 were  able  to
demonstrate that the percutaneous transplan-
tation of culture-expanded bone marrow cells
and  platelet-rich  plasma  accelerates  bone
regeneration during distraction osteogenesis
and thereby reduce overall complication rates.2
However, the directives for the expansion, dif-
ferentiation  and  re-transplantation  of  bone
marrow  cells  in  Europe  follow  certain,  very
strict requirements.3 There are also potential
risks, such as contamination or depletion of
proliferative  capacity,  as  well  as  additional
costs,  including  personnel  expenses,  culture
instruments,  chemicals,  and  contamination
tests.2,4 Furthermore,  a  one-step  procedure
with on-table preparation for immediate trans-
plantation may prevent complications related
to a reduced quality of the transplanted cells,
such as pre-aging, reduced viability, or dedif-
ferentiation (all of which are associated with
in vitro cultivation).5,6
In the treatment of aseptic non-unions, per-
cutaneous injection of autologous bone mar-
row aspirate has been shown to be clinically
effective.7,8Hernigou et al.were able to demon-
strate that efficacy seems to be related to the
number  of  progenitor  cells  in  the  graft.9
Therefore, the authors concentrated the bone
marrow aspirate for increasing the number of
progenitor  cells  before  intraosseous  reinjec-
tion at the site of non-union.9 Recently, there
have been reports with promising results on
transplantation  of  bone  marrow  concentrate
for poor-healing bone sites.10-13 The advantage
of concentrated bone marrow aspirate relies
on the possibility of on-table preparation and
reinjection in one operation without the need
to take the cells from the operation room into
a laboratory. The positive results of this new
technique together with the on-table prepara-
tion were the motivation to test the feasibility
for distraction osteogenesis.
Materials and Methods
This prospective study was approved by the
ethics  committee  of  the  Ruhr  Universität
Bochum,  Germany  (ethical  approval  number
3594-09). All patients gave their written con-
sent to participate in this study.
Between June 2009 and August 2010, two
female  and  six  male  patients  aged  22-64
(mean  44.4)  years  with  posttraumatic  bone
defects of the tibia were admitted to our clinic
(Table 1). All patients were treated with differ-
ent operative procedures before attending our
clinic, with a mean of 4.8 prior operative proce-
dures. Patients who reported prior treatment
after open trauma and posttraumatic infection
were treated with debridement, bone resection
and soft-tissue coverage by local and free flaps
and temporary stabilisation with a monolateral
fixator  (Figure  1).  The  sizes  of  the  bone
defects were between 44 and 126 mm (mean
82.4 mm). A free flap transfer was necessary in
two patients (Patients 1 (latissimus dorsi flap)
and 5 (anterolateral thigh (ALT) and latissimus
dorsi flap)  and  local  flap  coverage  in  five
patients (Patients 2-4, 7, 8). After soft-tissue
healing, the monolateral external fixation was
replaced by an Ilizarov ring fixator. Segmental
bone  transport  was  performed  using  an
intramedullary cable transport system (Figure
2). For distraction osteogenesis, percutaneous
osteotomy  of  the  proximal  tibia  (Gigli  saw)
was performed in the seven cases of antero-
grade  transport;  percutaneous  osteotomy  of
the distal tibia was performed in the case of
retrograde transport. The bone segment trans-
port was started after a delay of 7 days. The dis-
traction rate was 1 mm/day in the anterograde
transport and 0.5 mm in the one patient with
retrograde transport. Six patients were heavy
smokers  before  bone  transport,  and  four  of
them  continued  to  smoke  throughout  the
entire treatment phase (Patients 1, 4, 5, 6).
Patients were taught to work the transport
clickers  by  themselves  during  the  first  days
after the operation and were seen every two
weeks for X-ray control of distraction progress.
At the time of the docking of the transported
segment, the patients were admitted to the hos-
pital. The cable system and transport clickers
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doi:10.4081/or.2012.e14were removed, and the transport-segment was
fixed to the frame with K-wires and/or half pins
in the operating room. Local debridement of the
docking  zone  and  autologous  bone  grafting
from  the  iliac  crest  were  performed  in  each
patient. Before harvesting the autologous bone
from the iliac crest, a total of 60 mL bone mar-
row aspirate was obtained by Jamshidi vacuum
aspiration from the same iliac crest. Thereby,
only  a  few  millilitres  were  aspirated  at  once
before the aspiration needle was placed in dif-
ferent areas of the iliac crest to ensure a cell-
rich aspirate. The bone marrow aspiration con-
centrate (BMAC) was produced via density gra-
dient  centrifugation  using  the  Smartprep2TM
centrifuge  (Harvest  Technologies,  Plymouth,
MA, USA), in accordance with the manufactur-
er’s  directions  in  the  operation  room.  After
centrifugation, the plasma was removed, and
cells were resuspended, leaving a total volume
of 8 mL. Two mL of autologous thrombin were
added to the cell suspension before transplan-
tation into the regenerate. The Jamshidi nee-
dle was used as a syringe and was placed under
X-ray control percutaneously in the centre of
the regenerate, and the BMAC-thrombin-sus-
pension was slowly injected. Both aspirate and
concentrate (2 mL were saved of each sample
for in vitro analyses) were analysed using flow
cytometry  (FACS)  regarding  the  containing
cells. The concentration factor was calculated
by the cell count-quotient BMAC/aspirate after
the centrifugation procedure.
Patients were regularly seen every two weeks
for frame and soft-tissue control and for retight-
ening  of  the  Ilizarov  screws.  X-rays  in  two
planes were taken every four weeks to evaluate
the healing of the docking zone and the regen-
erate. Frames were removed when bony healing
with at least three cortices was present in both
the regenerate and the docking zone. Peri- and
postoperative  complications  were  divided  to
frame-associated  complication,  BMAC  trans-
plantation-associated  complications  and  com-
plications  not  related  to  the  procedures.  The
healing index (=time in frame (in days)/length
of regenerate (in cm)) and the consolidation
index (=time in frame after distraction phase
[in  days)/length  of  the  regenerate  (in  cm)]
3after BMAC transplantation were calculated.
Results
Bony  consolidation  of  the  regenerate  was
achieved  in  all  patients.  The  mean  healing
index was 36.9 d/cm (range 27.9 to 48.6) while
the mean consolidation index was 23.1 d/cm
(range 14.8 to 32.7; Table 1). The mean dis-
traction  phase  lasted  for  107  (60-156)  days.
The longer distraction phase in relation to the
mean defect size was caused by different fac-
tors. Retrograde transport (Patient 2) was per-
formed with 0.5 mm/d, which doubled the dis-
traction  phase  in  this  patient.  Furthermore,
the longer defect sizes (Patients 3-8) required
an exchange of the distraction clickers with re-
tensioning of the cable. During that procedure,
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Figure 1. X-rays (anterior (A) and lateral
view (B)) of Patient 7 at the day of admis-
sion with central bone defect after an open
fracture of the tibia (Gustilo type III B).
Figure 2. X-rays (A, B) of Patient 7 during the distraction phase (anterograde bone seg-
mental transport) and clinical picture (C) of the Ilizarov external frame with the applied
cable system and transport clickers.
Table 1. Mean bone defect size, soft tissue procedure, healing index and consolidation
index.
Patient Age Sex Bone Additional soft tissue HI CI in Follow up
defect procedures in d/cm d/cm in
in mm months
1 51 m 60 Latissimus dorsi free flap 42.7 32.7 14
2 44 m 44 Local flap 48.6 25.4 10
3 50 f 85 Local flap 28.5 16.9 13
4 42 m 97 Local flap 43.7 31.3 15
5 42 m 96 Anterior lateral thigh free flap,
Latissimus dorsi free flap 40.1 23.9 13
6 40 m 81 None 35.2 22.2 9
7 22 m 70 Local flap 27.9 14.8 5
8 64 f 126 Local flap 28.7 17.5 4the bone segment slipped back several mm in
the reverse-direction of transport. During the
distraction  phase,  patient  4  suffered  from  a
distal femoral fracture due to an accidental fall
on the same leg. This fracture was fixed with a
percutaneous  locking-plate  system  (NCB,
Zimmer,  USA).  In  Patient  5,  the  previously
transplanted ALT-flap showed partial necrosis,
which exposed the bone ends in the docking
zone. Before the docking procedure, coverage
with a latissimus dorsi flap was necessary, and
the BMAC procedure was performed after soft-
tissue healing to reduce the risk of infection. 
Local  pin  infections  were  seen  in  six
patients (Patient 2, 4, 5-8) and were treated
with local skin incision and oral antibiotics. No
pin or wire removal was necessary. With regard
to  major  complications,  Patient  2  displayed
non-union  of  the  docking  site.  The  patient
refused any further surgery and was treated
with  a  leg  brace.  However,  the  regenerate
showed sound bony healing. 
At the mean follow-up of 10.4 months after
removal of the frame, all patients except patient
2 were able to walk at full weight-bearing with-
out the help of crutches. Figures 3 and 4 show
the radiological results of Patient 7 and 8. No
adverse effects of cell injection into the regener-
ate were seen. The in vitro analysis of aspirate
and BMAC showed that the percentage of cells
was not changed signifantly by the centrifuga-
tion  process  (percentage  of  cells  before/after
centrifugation: granulocytes 75.9/76.6; lympho-
cytes 17.7/16.9; monocytes 3.1/3.6; CD34+1.1/1.3;
CD45-/CD90+ 0.76/0.93). The average concen-
tration factor of the BMAC compared to the
aspirate was 4.6 (SD 1.23).
Discussion
Several experimental studies demonstrated
that transplantation of progenitor cells into a
bone-healing  site  improves  bone  forma-
tion.4,14,15This suggests that in many situations
tissue and bone repair may be limited by the
presence and number of local progenitor cells.4
There are different approaches to increase the
population of these cells, but there is prelimi-
nary evidence that local application of these
cells may be of benefit:16,17 either immediate
implantation of harvested cells from bone mar-
row aspiration or transplantation of cells after
culture expansion and differentiation. The lat-
ter approach is already in clinical use for carti-
lage repair18-20 but has also been proven clini-
cally effective in distraction osteogenesis.2,21-23
Connolly et al.7 and Garg et al.8 suggested a
beneficial  effect  of  the  percutaneous  trans-
plantation of autologous bone marrow aspirate
in cases of non-union in long bones. Hernigou
et al. demonstrated that by centrifugation of
bone marrow aspirate, the mononuclear cells
can  be  concentrated,  resulting  in  further
enhancements of osteogenesis.9 The effective-
ness  of  the  BMAC  procedure  in  harvesting
mononuclear  cells,  including  mesenchymal
stem cells, has been demonstrated in different
studies.10,24,25 Jäger et al. showed that relevant
amounts  of  potent  mesenchymal  stem  cells,
which differentiate into osteoblasts in vitro,
can be harvested with the BMAC system.10 The
mean concentration factor of 4.6 that we found
in the present study lies between the results
presented by Hermann et al. (mean factor of
4.4)25 and Jäger et al. (mean factor of 5.2).10
Very recently, other authors have demonstrat-
ed  beneficial  effects  on  bone  healing  in
patients with bone cysts, osteo-necrosis and
non-unions  with  the  transplantation  of
BMAC.5,10,11,13,26 To  the  knowledge  of  the
authors, the procedure has not been described
for distraction osteogenesis.
Three  essentials  constituents  have  been
assumed besides biomechanical stability and
vascularization in accelerating new bone for-
mation (referred to as the diamond concept):
growth  factors,  osteoprogenitor  cells  and
extracellular  matrix/natural  scaffold.27 The
BMAC  system  provides  the  first  two  con-
stituents. The third - the natural scaffold - is
generated  during  the  distraction  process:
During the distraction phase a fibrovascular
lattice is generated between the two distracted
bone ends, which consist of longitudinally ori-
ented fibrous connective tissue with a protec-
tive  covering  membrane.28,29 The  BMAC  was
injected  at  the  end  of  the  distraction  phase
into this membranaceous tube that is assumed
to function as a natural scaffold for the cell
suspension. It has been shown that a so-called
growth zone forms in the centre of the length-
ening  segment,  in  which  no  ossification
occurs  until  the  consolidation  phase
begins.28,29 In a patient treated previously to
the present study we could visualize the diffu-
sion  of  non-concentrated  iliac  crest  blood
mixed with a contrast medium in the centre of
the regenerate (Figure 5). Furthermore, the
addition  of  autologous  thrombin  transferred
the fluid cell suspension into a viscous, gel-
like constitution, and may lead to a local adher-
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Figure 3. X-rays of Patient 7 four months
after frame removal with bony consolida-
tion both of the regenerate and the distal
docking site. 
Figure 4. X-rays of Patient 8 with a pathologic fracture due to a chronic osteomyelitis at the day
of admission (A, B) during transportation (C) and five months after frame removal (C, D, E).ence of the injected cells as described similar-
ly by Schmelzeisen et al.30 for maxillary sinus
application.
This feasibility study suffers from the small
number  of  patients  and  a  missing  control
group, which is a problem of many cell-based
clinical  studies.5,9,10,30,31 Bone  healing  in  dis-
traction osteogenesis is a complex process that
is dependent on various parameters such as
age,  epidemiology  of  bone  loss,  soft-tissue
envelope, and fixation device. This makes it
even more difficult to compare the healing or
consolidation index with other studies. In gen-
eral, longer healing indices have been report-
ed for segmental transports in posttraumatic
and/or  (post-)infected  patients  compared  to
callus  distraction  in  non-injured  regions.
Under  these  difficult  conditions,  healing
indices up to 4.6 month/cm and the time in
frame up to 54 months have been reported, and
the rate of callus insufficiency is significantly
higher.32-35 Especially  poor  soft-tissue  condi-
tions,  restricted  blood  supply  and  nicotine
abuse are risk factors. In cases of long-size
transports, the docking site usually heals long
before  consolidation  of  regenerate  occurs.1
Although all patients presented with posttrau-
matic bone loss and all but one needed addi-
tional flap coverage, we did not observe insuf-
ficiency of the regenerate. Four patients also
continued to smoke throughout the treatment.
The mean HI of 36.9 d/cm and CI of 23.1 d/cm
appear rather short in comparison to the above
named studies concerning posttraumatic bone
defects but must be interpreted with care due
to limitations of the present feasibility study. 
Conclusions
Accelerating the consolidation phase during
distraction osteogenesis and prevent insuffi-
ciency of the callus is of great need in clinical
practice. The safety demands for an augmenta-
tion procedure must be very strict; the tech-
nique needs to be of minimal risk and minimal
invasiveness,  without  compromising  the
regenerated  callus  and  surrounding  soft  tis-
sues. Based on the recent literature and these
preliminary results, this seems to apply for the
BMAC  procedure.  We  did  not  detect  any
adverse effects on the side of harvesting or at
the regenerate. Further studies with a larger
number  of  patients  and  a  control  group  are
needed to evaluate the effects on accelerated
regenerate healing.
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